Price Momentum and Recent Trading Range
On 2 January 2026, Strides Pharma closed at ₹911.95, up from the previous close of ₹902.35, marking a daily increase of 1.06%. The stock traded within a range of ₹878.25 to ₹917.00 during the session, reflecting moderate intraday volatility. The current price remains below its 52-week high of ₹1,024.90 but comfortably above the 52-week low of ₹530.70, indicating a recovery trajectory over the past year.
Year-to-date, Strides Pharma has delivered a modest return of 1.06%, slightly outperforming the Sensex’s marginal decline of 0.04% over the same period. Over longer horizons, the stock has significantly outpaced the benchmark, with a one-year return of 29.91% compared to Sensex’s 8.51%, and an impressive three-year return of 443.96% against the Sensex’s 40.02%. This strong relative performance underscores the company’s resilience and growth potential within the Pharmaceuticals & Biotechnology sector.
Technical Indicator Analysis: Mixed Signals
The technical landscape for Strides Pharma is characterised by a blend of bullish and bearish signals across different timeframes and indicators. The overall technical trend has shifted from bullish to mildly bullish, suggesting a cautious optimism among traders and analysts.
The Moving Average Convergence Divergence (MACD) indicator, a key momentum oscillator, remains mildly bearish on both weekly and monthly charts. This suggests that while short-term momentum may be waning, the longer-term trend has not decisively turned negative. The Relative Strength Index (RSI) on weekly and monthly timeframes currently shows no clear signal, indicating neither overbought nor oversold conditions, which may imply a consolidation phase.
Conversely, Bollinger Bands on weekly and monthly charts maintain a bullish stance, signalling that price volatility is contained within an upward trending channel. Daily moving averages also support a bullish outlook, reinforcing the notion that the stock’s short-term price action remains constructive.
The Know Sure Thing (KST) indicator presents a split view: bullish on the weekly chart but mildly bearish on the monthly chart. This divergence highlights the potential for short-term gains amid longer-term uncertainty. Dow Theory analysis aligns with this, showing a mildly bullish trend on the weekly timeframe but no definitive trend on the monthly scale.
On-Balance Volume (OBV), a volume-based indicator, is mildly bullish on the weekly chart, suggesting that buying pressure is slightly outweighing selling pressure in the near term. However, the monthly OBV shows no clear trend, reinforcing the mixed technical environment.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Mojo Score and Rating Upgrade
Reflecting these technical developments, Strides Pharma’s Mojo Score currently stands at 50.0, with a Mojo Grade of Hold. This represents an upgrade from a previous Sell rating as of 29 September 2025, signalling improved investor sentiment and a more balanced risk-reward profile. The company’s market capitalisation grade is 3, indicating a mid-tier valuation relative to its peers in the Pharmaceuticals & Biotechnology sector.
This rating adjustment aligns with the observed technical trend shift from bullish to mildly bullish, suggesting that while the stock is not yet a strong buy candidate, it has moved out of a bearish phase and may offer selective opportunities for investors with a medium-term horizon.
Comparative Performance and Sector Context
Strides Pharma’s performance relative to the Sensex and its sector peers is noteworthy. Over the past five years, the stock has delivered a return of 115.48%, comfortably exceeding the Sensex’s 77.96% gain. However, over a decade, the Sensex’s 225.63% return outpaces Strides Pharma’s 45.51%, reflecting the stock’s more recent acceleration rather than sustained long-term dominance.
Within the Pharmaceuticals & Biotechnology sector, Strides Pharma’s technical and fundamental profile positions it as a stock with solid momentum but also some cautionary signals. Investors should weigh the mildly bearish MACD and mixed KST readings against the bullish moving averages and Bollinger Bands to gauge entry points and risk management strategies.
Why settle for Strides Pharma Science Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Investor Takeaway and Outlook
For investors considering Strides Pharma Science Ltd, the current technical signals suggest a cautious but constructive environment. The mildly bullish trend indicates potential for further gains, supported by daily moving averages and Bollinger Bands. However, the mildly bearish MACD and mixed KST readings counsel prudence, especially for those seeking strong momentum confirmation.
Given the stock’s recent upgrade from Sell to Hold and its balanced Mojo Score, investors may consider accumulating on dips or monitoring for a clearer breakout above resistance levels near ₹1,000. The stock’s relative outperformance over one and three years versus the Sensex highlights its growth credentials, but the absence of strong monthly momentum signals suggests that patience may be required for sustained upward moves.
Overall, Strides Pharma remains a noteworthy contender within the Pharmaceuticals & Biotechnology sector, combining solid fundamentals with a technical profile that warrants close attention as market conditions evolve.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →
